Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
absent, accrete, ADHD, Ajer, analytical, arylsufatase, ASCEND, awaiting, benchmark, BRCA, Bulletin, Catalyst, cease, characterized, Comission, Computershare, CRO, Daniel, deprecation, drove, dwarfism, eighteen, EMA, entitieson, environment, EPO, estimatable, Ewing, exceeding, glycan, glycolipid, hurdle, hyperactivity, inattention, inflow, Jeffery, licensure, mandated, mandatory, master, merger, mindful, neuropsychiatric, ofapproximately, outweigh, passage, PDUFA, placebo, potency, prelaunch, prepaid, professional, purity, reallocate, repeat, repeated, Russia, SAB, salesforce, sarcoma, searchable, Shareowner, short, Spiegelman, statistically, steady, stimulate, strength, thesematerial, unblinding, underwritten, unrepatriated, Vimizim, VimizimTM, waiver, web, worsening, Zacharon
Removed:
abusive, affiliate, amending, antikickback, approximated, Ascent, assignment, assuming, attached, capitalizing, close, commenced, decided, devote, Digital, disregarded, Eaton, eliminate, encoding, entitle, EUSA, executed, existence, FDAAA, feature, finally, forming, futile, genomic, guard, hold, identical, influenced, interim, isolated, Jolla, la, Lambert, liquidation, nucleotide, offered, optimal, Orapred, Pacific, post, presumption, prompt, proportionate, remedy, representing, Riquent, secured, Shionogi, slight, sublicensed, suffered, superior, takeover, tender, thirty, upholding, wrong
Filing tables
Filing exhibits
Related press release
BMRN similar filings
Filing view
External links
Exhibit 23.2
CONSENT OF INDEPENDENT ACCOUNTANTS
We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-181697, 333-168552, 333-136963, 333-85368 and 333-84787) and Form S-3 (333-181766) of BioMarin Pharmaceutical Inc. of our report dated February 24, 2011 relating to the financial statements of BioMarin/Genzyme LLC, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
Boston, Massachusetts
February 26, 2013